SCHEMBL4971902

SCHEMBL4971902

CN(Cc1cccc(-c2ccc(CCC(=O)O)cc2)c1)C(=O)CCCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 12/20 0.60
KMT2A Q03164 1/20 0.57
FFAR1 O14842 6/20 0.56
FFAR4 Q5NUL3 2/20 0.56
AKR1B1 P15121 1/20 0.53
PPARG P37231 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4970598 0.90 AOC3 (0.53) AOC3KMT2AFFAR1FFAR4
SCHEMBL4968795 0.79 AOC3 (0.46) AOC3KMT2A
SCHEMBL4969484 0.79 FFAR1 (0.48) AOC3FFAR1FFAR4
SCHEMBL4971682 0.78 AOC3 (0.48) AOC3KMT2APPARG
SCHEMBL4969521 0.78 PTGER4 (0.47) AOC3FFAR1FFAR4AKR1B1
SCHEMBL11368767 0.77 AOC3 (0.72) AOC3
SCHEMBL4970036 0.77 AOC3 (0.44) AOC3KMT2A
SCHEMBL4969558 0.77 AOC3 (0.48) AOC3KMT2AFFAR1
SCHEMBL4969992 0.77 AOC3 (0.48) AOC3KMT2AFFAR1
SCHEMBL4968446 0.76 FFAR1 (0.48) AOC3KMT2AFFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-06 US claimed
EP-1781274-B1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-11-05 EP disclosed
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-06 US disclosed
EP-1781274-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2007-05-09 EP disclosed
WO-2006018325-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD AOC3 2115/4885KMT2A 3074/4885FFAR1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.